.hypercvad / Ma Program, Clinical Observations, Treatment Of 22 Cases Of Tumor Of The Lymphatic System

Objective: To evaluate the efficacy and safety of hyperCVAD/MA as an intensification regimen in the treatment of patients with adult acute lymphoblastic leukemia and aggressive none-Hodgkin lymphoma in China.Methods: To summarize and retrospective analyze 22 patients with adult ALL and aggressive lymphoma in our department from July, 2004 to January,2006 and investigate the efficacy and side-effect of this regimen. Kaplan-Meier method is applied to analyze the rate of overall survival (OS)and disease-free survival. Results: 1) There are 17 males and 5 females in all 22 patients, including 6 cases of acute lymphoblastic leukemia with Philadelphia chromosome or BCR/ABL fusion gene, 2 cases of acute hybrid leukemia with Philadelphia chromosome or BCR/ABL fusion gene, 6 cases of acute lymphoblastic leumkemia without philaderphia chromosome or BCR/ABL fusion gene and 8 cases of advanced aggressive none-Hodgkin lymphoma. The median age is 22.5(14-45) years. 2) 22 patients have received 37 courses hyperCVAD/MA all together,and the major toxicities are III-IV stage hematological toxicity and none-hematological toxicity including hepatotoxicity and gastrointestinal track toxicity. Hematological toxicity of even courses MA in therapeutic cycle is severer than in odd courses. But all side-effect has been managed easily and converted after treatment. There is no treatment related mortality. 3) After a median two courses of hyperCVAD/MA,5 patients received autogeneic peripheral blood stem cell mobilization and collection.2 poor mobilization have been observed, and the median count of MNC and CD34~+ is 4.03 × 10~8/kg and 0.65 × 10~6/kg, respectively. 4) In 13(5~23)months of the median of follow-up time, overall survival time and the rate of overall survival of 12 months and 23 months is 21 months and 87.4% ±8.4% , 45.9% ± 16.9%,respectively. 6 patients died in relapse(4 patients) or transplantation-related complication (2 patients). 5)After intensification therapy, 10 of 22 patients received hematological stem cell transplantation(HSCT), include 5 cases of allogeneic HSCT and 5 cases of autogeneic HSCT. All patients maintain disease-free survival from one month to fourteen months...